INTRODUCTION

Medulloblastoma is the most common malignant brain tumor of childhood(1).
Patients with local disease receive surgical resection, radiation therapy and chemotherapy, with five-year overall-survival exceeding 80% (2) . These treatments cause significant therapy-related morbidity, including disabling cognitive deficits(3), growth failure, and increased risk of secondary malignancies (4) . However, despite intensive chemotherapy and radiotherapy, the overall survival of these "high-risk" patients remains dismal, with 10-year overall-survival rates as low as 20% (5) . Thus, tremendous impetus exists for the development of more effective treatments, based on known molecular targets, in medulloblastoma.
Medulloblastoma is a genetically heterogeneous disease, comprised of molecular subtypes characterized by differing transcriptional signatures, genomic alterations, and clinical courses (6) (7) (8) (9) . The current consensus is of at least four distinct subtypes including Wingless (WNT), Sonic Hedgehog (SHH), Groups 3 and 4 (10) . Group 3 medulloblastomas have the worst prognosis, are commonly metastatic and refractory to standard therapy, with 10-year overall-survival rates of 39% (5, 6, 10) . Amplifications of one of three members of the MYC family of genes (MYC, MYCN, MYCL1) are found in several subtypes. Group 3 tumors are often associated with amplification of MYC (11) , which is the most frequently observed amplification observed across multiple cancer types (12) . Author Manuscript Published OnlineFirst on December 2, 2013; DOI: 10.1158/1078-0432.CCR- MYC (6) or amplification of MYCN (11) . MYCL1 amplifications have been reported in a few SHH tumor cases while SHH and Group 4 tumors are enriched with amplifications of MYCN (11) .
MYC and other transcription factors complicit in cancer are poor targets for small molecule inhibition.
Alternative strategies target MYC through epigenetic modulation of MYC transcription itself or of MYC target genes (13, 14 Figure 1A ) (11) . MB004 cells were derived from the primary surgical resection of a tumor in a child whose tumor recurred after therapy. The MB004 primary tumor displayed focal anaplasia and gene expression markers consistent with Group 3 and Group 4 medulloblastoma (see Supplemental Figure 1 ) (6) . MYC-amplification in the MB002 and MB004 cells were confirmed with NanoString nCounter v2 Cancer CN Codeset, which
Research. 
Over-expression of MYC in D283 for MYC rescue experiments
293T cells were transfected with 2 μg retroviral pBabe expression vectors (empty vector or pBabeMYC) with packaging plasmids encoding gag-pol and VSVG using Lipofectamine. Retro-virus containing supernatant was collected at 48 hours and 72 hours after transfection, pooled and stored at -80 °C. D283 ells were infected (ratio of 1:4 virus media) in polybrene-containing media (2.5μg/ml).
Treatment with 1μM JQ1R or JQ1S was commenced at six hours post infection.
Cell viability was assessed at 24 hours post treatment with JQ1.
Cell viability assays following treatment with JQ1 or shRNA suppression
Research. To assess responsiveness to JQ1, 1000 cells were plated in 96-well plates in serial dilutions of either JQ1R or JQ1S, in triplicate. Cell viability was measured by assessing ATP content at 0, 24, 48, 72, 96 and 120 hours using Cell Titre-Glo (Promega) according to the manufacturer's instructions. Mean ± standard deviation (SD) was calculated. Non-linear dose response curves were applied to the data using GraphPad Prism.
To assess dependence of cells on BRD4 or MYC, cells were infected with lentiviral plasmids encoding shRNA. Forty-eight hours after infection, 1000 cells were plated in each well of 96-well plates, in triplicate, in media containing puromycin(1μg/ml). Cell viability was measured by assessing ATP content using Cell Titre-Glo (Promega), and results were normalized to baseline. Mean ± SD was calculated.
Flow Cytometry
Cell cycle analysis was performed by measuring DNA content by Propidium 
RNA extraction and Real-Time RT-PCR
RNA was extracted with the RNeasy kit (Qiagen). cDNA was synthesized from 1µg RNA using High Capacity RNA to cDNA kits (Applied Biosystems). Realtime RT-PCR was performed using SYBR Green master mix (Applied Biosytems). Cycling was performed as follows: 50°C for two minutes and 95°C for ten minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 30 seconds. This was followed with a dissociation stage of 95°C for 15 seconds, 60°C for 30 seconds, and 95°C for 15 seconds. Primers for BRD4, MYC and β-actin are listed in Supplemental Table 2 . Samples were amplified in triplicate and data analyzed using the ΔΔC T method.
Copy-number analysis
Relative copy-number estimates were generated from published Affymetrix SNP 6.0 data for 1073 tumors (11) and an analytic pipeline described in detail elsewhere (Tabak et al, in preparation). Briefly, signal intensities for each probe were normalized to uniform intensity values and merged to form probeset-level values using SNPFileCreator, a Java implementation of dChip (21, 22) . Marker-level intensities were calibrated to DNA copy-number levels using Birdseed for SNP markers (23) and using the results of experiments with cell lines with varied copy-numbers of the X chromosome for copy-number probes (Tabak et al., in preparation). Regions of frequent germline copy-number variation were identified using a large bank of normal tissue samples and excluded from the data (Tabak et al, in preparation).
Noise was reduced by applying Tangent normalization (12) followed by Circular Binary Segmentation (24, 25) . Data were mean-centered for each sample.
Amplifications were defined as greater than a relative copy-number of 2.4. For samples with a relative copy-number of 2.4 to 3, we applied the ABSOLUTE algorithm (26) and confirmed that each of these samples had an absolute copynumber of greater than three copies.
Genome-wide expression analysis
Previously published microarray expression and copy number data(11) were obtained from the Gene Expression Omnibus (GSE37385 and GSE37382). The expression data were obtained using the GEOImporter module in GenePattern. Table 2 ). Gene sets with a nominal p-value less then 0.05 were considered significant.
To examine the effect of JQ1 on global gene transcription, cell lines were treated with JQ1R or JQ1S (1μM for 24 hours) and RNA was extracted. Gene expression profiles were assayed using Affymetrix Human Gene 1.0 ST microarrays (Affymetrix, Santa Clara, CA). CEL files were normalized using
RMA(29). Expression-array data have been deposited in the Gene Expression
Omnibus portal under the accession number GSE51020. Comparative marker selection analysis(30) between JQ1S-and JQ1R-treated cells was performed in GenePattern using the default settings.
The recently-described JQ1 consensus signature (16) 
RESULTS
Medulloblastomas exhibit several indicators of MYC pathway activation
We evaluated indicators of MYC pathway activation using integrated datasets of genome-wide copy-number estimates from 1071 medulloblastomas and corresponding gene expression data for 282 medulloblastomas (11) 
of MYC activation (Supplemental Table 2 ) and comparing tumors with high expression of any MYC to tumors with low expression of all MYCs. Among the nine MYC activation signatures present in our gene sets, six were significantly associated with high MYC expression, five with MYCN and four with MYCL1, respectively (Supplemental Table 3 ).
Medulloblastomas that exhibited indicators of MYC activation also exhibited high expression of genes observed to be down-regulated with treatment with the BET bromodomain inhibitor JQ1 (16) . 
JQ1 reduces cell proliferation in MYC-and MYCN-amplified medulloblastoma cells
We examined the efficacy of treatment with JQ1S in six patient-derived medulloblastoma cell lines documented to have MYC-amplification relative to five non-MYC amplified medulloblastoma lines, and human neural stem cells (34, 35) .
Western immunoblotting of the patient-derived cell lines confirmed increased expression of MYC in lines with MYC-amplification (Supplemental Figure 1B) .
No patient derived MYCN-amplified medulloblastoma cell lines have been generated to date, therefore we evaluated JQ1 activity in the setting of Mycnamplification using tumor cells derived from recently developed mouse models of group 4 MYNC-amplified medulloblastomas (18, 36) . We also evaluated JQ1 activity in a murine model of group 3 MYC-driven medulloblastoma. The activity of JQ1 was initially assessed by comparing proliferation rates in the presence of the active stereoisomer of JQ1 (JQ1S) to proliferation rates in the presence of an inactive stereoisomer, JQ1R (13) .
In all MYC-amplified patient-derived cell lines, treatment with JQ1S for 48 hours at doses less than 1μM resulted in 57-69% reduction in cell viability compared to treatment with JQ1R ( Figure 2A) . Each MYC-amplified line had an IC50 of less than 1μM. In contrast, cell viability of non-MYC amplified cell lines ( Figure 2B) and neurons derived from the subventricular zone (SVZ) ( Figure 2C 
BRD4 suppression attenuates expression of MYC in medulloblastoma cells
We hypothesized that the effects of JQ1 in the medulloblastoma cells were mediated in large part by decreased activity of MYC through inhibition of BRD4.
BRD4 has been shown to be a cofactor for MYC-dependent transcription in multiple cell types (13) , and JQ1 has previously been shown to have higher affinity for binding domains of BRD4 than other bromodomain-containing proteins (13) . We therefore suppressed expression of either MYC or BRD4 in each of the six MYC-amplified patient derived cell lines using MYC-and BRD4-directed shRNAs. We measured proliferation and compared the results to controls treated with LacZ-targeted shRNAs. Suppression of MYC and BRD4 protein levels was confirmed by immunoblotting ( Figure 4A and Supplemental Figure 3 ).
In all cell lines, suppression of either MYC or BRD4 resulted in greater than 50% reductions in proliferation relative to cells treated with LacZ-targeted shRNAs ( Figure 4B ). We observed absolute decreases in cell numbers among four lines with both MYC suppression and BRD4 suppression.
In all cell lines, suppression of BRD4 was also associated with a reduction of MYC mRNA, by an average of 45% relative to the LacZ-suppressed controls (p<0.0001; Figure 4C ). We also observed a reduction in MYC protein levels in 
JQ1 suppresses MYC activation pathways and expression of MYC and MYCN themselves
To determine the transcriptional effects of JQ1 treatment, we performed genomewide expression profiling of five patient-derived MYC-amplified cell lines treated with 1 μM of either JQ1S or JQ1R for 24 hours. We identified 43 genes that were significantly down-regulated by JQ1S (FDR<0.1; Supplemental Table 4 ). No genes were significantly up-regulated at this significance threshold.
The JQ1S-treated cells exhibited significant enrichment of a signature of JQ1 treatment derived from multiple myeloma, leukemia and neuroblastoma cells (16) (p<0.0001; Figure 5A ), and significant attenuation of MYC activity (p<0.05 in all cases; Figure 5B ). An unbiased screen of pathways altered by treatment with Ongoing work, however, is required to determine optimal strategies to incorporate these agents into upfront therapy for children with newly diagnosed MYC-amplified medulloblastoma. Specifically, further work is required to assess strategies to combine BET-bromodomain inhibition with other treatment modalities such as radiation therapy and chemotherapy. Specific predictors of sensitivity and resistance to JQ1 remain to be elucidated. 
We show that MYC-amplified medulloblastomas can be targeted by epigenetic modulation of oncogenes. BRD4 is an epigenetic reader that binds to ε-N-lysine acetylation motifs (41) . It is increasingly recognized that genomic alterations may result in global epigenetic dysregulation in pediatric brain tumors (42) (43) (44) . Indeed, Group 3 medulloblastomas have been found to harbor somatic copy number alterations of genes involved in chromatin modeling (45, 46) . These alterations frequently affect genes of modifiers of H3K27 methylation (46) . Thus, it is possible that targeting other chromatin modifiers may also have activity in this group of tumors. Further work is required to define the interplay between methylation and acetylation of these histone marks to help determine whether the combination of different classes of epigenetic modulators may improve their efficacy.
We were unable to obtain any patient derived medulloblastoma cell lines that harbor amplifications of either MYCN or MYCL1. Our integrative analysis of copy number and expression profiles suggest that both isoforms are associated with increased expression of MYC activation pathways, suggesting that BETbromodomain inhibition may be effective in tumors that harbor these amplifications.
Indeed, BET-bromodomain inhibition has been shown to suppress MYCN expression in patient derived neuroblastoma cell lines (16) . We have shown efficacy of JQ1 treatment in a cell line generated from a MYCNdriven mouse model, however ideally this should be validated in patient-derived
MYCN-amplified medulloblastoma cell lines.
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In summary, we show that BET bromodomain inhibition results in suppression of MYC activation pathways in MYC-driven medulloblastoma models, resulting in reduced cell viability, induction of G1 arrest and apoptosis with prolongation of survival in xenograft models. These data provide a rationale for early phase clinical trials for BET bromodomain inhibitors for children with this aggressive disease.
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